Redesigned Transforaminal Lumbar Device Provides Amedica with Broader Interbody Fusion Device Market Opportunities
Amedica Corporation (Nasdaq:AMDA), a commercial biomaterial company focused on silicon nitride ceramics as a material platform to develop, manufacture and sell novel medical devices, is pleased to announce the release of its second generation silicon nitride transforaminal lumbar (TL) interbody fusion device. The Valeo II™ TL interbody fusion device includes optimized instrumentation to improve patient safety and surgeon ease of use, while maximizing central cavity space for autograft packing to facilitate fusion through the implant.
The Valeo II™ TL is made of a micro composite silicon nitride biomaterial, which offers a superior environment for bone growth and osteointegration, when compared to competitive PEEK and titanium offerings. Valeo II™ TL silicon spinalnitride interbody fusion devices also contain anti-infective properties and are semi-radiolucent with clearly visible boundaries in x-rays and produce no artifacts under MRI or CT scans. The combination of these properties is found only in Amedica’s silicon nitride biomaterial technology.
“With more than 20,000 implants to-date of our Valeo products, we’re proud to further expand our line of silicon nitride spinal interbody offerings,” said Eric Olson, CEO and President of Amedica. “This second generation TL device, in tandem with our anterior, posterior and oblique lumbar second generation silicon nitride interbody devices, greatly strengthens our ability to capture additional share within the $1.4 billion spinal interbody fusion device market. We remain dedicated to bringing new and innovative solutions to the market that we believe offer distinct benefits to improve the efficacy of spinal fusion procedures, resulting in enhanced patient care.”
The Valeo II™ TL is indicated for intervertebral body fusion of the spine in skeletally mature patients and is designed for use with autograft to facilitate fusion.